A class action lawsuit has been filed against Regenxbio Inc. and certain officers, alleging violations of federal securities laws. The complaint claims that, between February 9, 2022 and January 27, 2026, the company made materially false and misleading statements regarding the development and commercialization of its gene therapy RGX-111, overstating its efficacy and safety. Investors who purchased Regenxbio securities during this period may be eligible to participate in the case, with an April 14, 2026 deadline to seek lead plaintiff status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602171200PRIMZONEFULLFEED9655382) on February 17, 2026, and is solely responsible for the information contained therein.